Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).

Authors

Bertrand F. Tombal

Cliniques Universitaires Saint-Luc, Brussels, Belgium

Bertrand F. Tombal , Yohann Loriot , Fred Saad , Raymond S. McDermott , Sandrine Marreaud , Laurence Collette , Silke Gillessen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM) – A multicenter analysis.

First Author: Aurelius Gabriel Omlin

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.

First Author: Steven E. Finkelstein

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.

First Author: Sten Nilsson

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.

First Author: Nicholas J. Vogelzang